2022
DOI: 10.1093/mtomcs/mfac041
|View full text |Cite
|
Sign up to set email alerts
|

A ferrocene-containing nucleoside analogue targets DNA replication in pancreatic cancer cells

Abstract: Pancreatic ductal adenocarcinoma (PDAC) is a disease that remains refractory to existing treatments including the nucleoside analogue gemcitabine. In the current study we demonstrate that an organometallic nucleoside analogue, the ferronucleoside 1-(S,Rp), is cytotoxic in a panel of PDAC cell lines including gemcitabine-resistant MIAPaCa2, with IC50 values comparable to cisplatin. Biochemical studies show that the mechanism of action is inhibition of DNA replication, S-phase cell cycle arrest and stalling of D… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(1 citation statement)
references
References 65 publications
0
1
0
Order By: Relevance
“…(GEM), classified as an antimetabolite chemotherapy agent, exerts its therapeutic effects primarily by disrupting the synthesis of Deoxyribonucleic Acid (DNA) and Ribonucleic Acid (RNA) within cancer cells. Through the inhibition of cellular division and replication processes, GEM obstructs cancer cell proliferation, thereby curbing tumor growth and spreading [4] . As reported, GEM, in the context of cancer, can transform into active metabolites and upon entry into cancer cells, phosphorylates into GEM diphosphate (dFdCDP).…”
Section: Gemcitabinementioning
confidence: 99%
“…(GEM), classified as an antimetabolite chemotherapy agent, exerts its therapeutic effects primarily by disrupting the synthesis of Deoxyribonucleic Acid (DNA) and Ribonucleic Acid (RNA) within cancer cells. Through the inhibition of cellular division and replication processes, GEM obstructs cancer cell proliferation, thereby curbing tumor growth and spreading [4] . As reported, GEM, in the context of cancer, can transform into active metabolites and upon entry into cancer cells, phosphorylates into GEM diphosphate (dFdCDP).…”
Section: Gemcitabinementioning
confidence: 99%